AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...

Calquence in combination with bendamustine and rituximab has been recommended for approval in the European Union, EU, for ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

(Sharecast News) - AstraZeneca announced on Monday that it secured a US regulatory approval and a positive EU recommendation for two of its oncology therapies, Imfinzi and Calquence, marking ...

chemoimmunotherapy alone AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult ...

Susan Galbraith, Executive Vice President of Oncology R&D at AstraZeneca, emphasized the potential of Calquence to transform the standard of care for MCL patients in Europe. MCL is a rare ...

Susan Galbraith, Executive Vice President of Oncology R&D at AstraZeneca, emphasized the potential of Calquence to transform the standard of care for MCL patients in Europe. MCL is a rare, typically ...